Safety and Clinical Management Safety trials of GLP-1 RAs, including liraglutide, tirzepatide, and semaglutide (oral or subcutaneous), indicate that the most common adverse events (AEs) of treatment are mild to moderate gastrointestinal including nausea, vomiting, diarrhea, constipation, dyspepsia, and decreased appetite
Sculptra, Radiesse (biostimulatory use), EZgel / PRF
R.GrossE
The escalation ladders are different in structure, but the principle is the same: start low, increase every 30 days, and stop at the dose that works best for the patient
Eshdat Y, Holland D, Faltin Z, Ben-Hayyim G (1997) Plant glutathione peroxidases
Kunal Shah, an assistant professor in the division of endocrinology at the Rutgers Robert Wood Johnson Medical Center in New Brunswick, New Jersey